WordNet
- type genus of the family Cancridae (同)genus Cancer
- the fourth sign of the zodiac; the sun is in this sign from about June 21 to July 22 (同)Cancer the Crab, Crab
- (astrology) a person who is born while the sun is in Cancer (同)Crab
- a small zodiacal constellation in the northern hemisphere; between Leo and Gemini
- any malignant growth or tumor caused by abnormal and uncontrolled cell division; it may spread to other parts of the body through the lymphatic system or the blood stream (同)malignant neoplastic disease
- relating to or involving the stomach; "gastric ulcer" (同)stomachic, stomachal
- relating to or affected by metastasis; "metastatic growth"
PrepTutorEJDIC
- 〈U〉〈C〉『がん』 / 〈U〉〈C〉害悪 / 《Cancer》(星座の)カニ座
- 胃の,胃に発生する
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
- 1. 限局進行性で切除不能の転移性食道癌および胃癌に対する全身療法 systemic therapy for locally advanced unresectable and metastatic esophageal and gastric cancer
- 2. 胃癌の臨床的特徴、診断、および病期分類 clinical features diagnosis and staging of gastric cancer
- 3. 進行性胃癌に対する局所緩和 local palliation for advanced gastric cancer
- 4. 浸潤性胃癌に対する外科的マネージメント surgical management of invasive gastric cancer
- 5. 成人における胃流出路閉塞 gastric outlet obstruction in adults
English Journal
- Gastric cancer progression may involve a shift in HLA-E profile from an intact heterodimer to β2-microglobulin-free monomer.
- Sasaki T, Ravindranath MH, Terasaki PI, Freitas MC, Kawakita S, Jucaud V.Author information Terasaki Foundation Laboratory, Los Angeles, CA; Department of Surgery, Jikei University School of Medicine, Tokyo, Japan.AbstractPhenotypic expression of human leukocyte antigen (HLA)-E on the surface of tumor lesions includes intact heterodimer [HLA-E heavy chain and β2-microglobulin (β2m)] and β2m-free monomer. Anti-HLA-E monoclonal antibodies (mAbs), MEM-E/02 or 3D12 bind to the peptide sequences in β2m-free HLA-E, which is common and shared with HLA-Ia monomers. A newly developed monospecific anti-HLA-E mAb (TFL-033) recognizes HLA-E-restricted peptide sequences on α1 and α2 helices away from β2-m-site. Tumor progression may involve shedding of β2-m from HLA-E or overexpression of β2m-free monomers. There is a need to identify and distinguish the different phenotypic expression of HLA-E, particularly the intact heterodimer from the β2m-free monomer on the surface of tumor lesions. Because of the unique peptide-binding affinities of the mAbs, it is hypothesized that TFL-033 and MEM-E/02 may distinguish the phenotypic expressions of cell surface HLA-E during stages of tumor progression. Only TFL-033 stained diffusely the cytoplasm of normal mucosa. The incidence and intensity of TFL-033 staining of the cell surface in early stages, poorly or undifferentiated and non-nodal lesions and in diffuse carcinoma is greater than that of MEM-E/02. Whereas MEM-E/02 stained terminal stages, adenocarcinoma and lymph node metastatic lesions intensely, either owing to increased expression of β2m-free HLA-E with tumor progression or owing to expression of HLA-Ia molecules. Our study evaluates the relative diagnostic potential of HLA-E-monospecific TFL-033 and the HLA-Ia-reactive MEM-E/02 for determining the specific distribution and immunodiagnosis of different phenotypic expression HLA-E in tumor lesions, and the structural and functional alterations undergone by HLA-E during tumor progression.
- International journal of cancer. Journal international du cancer.Int J Cancer.2014 Apr 1;134(7):1558-70. doi: 10.1002/ijc.28484. Epub 2013 Dec 11.
- Phenotypic expression of human leukocyte antigen (HLA)-E on the surface of tumor lesions includes intact heterodimer [HLA-E heavy chain and β2-microglobulin (β2m)] and β2m-free monomer. Anti-HLA-E monoclonal antibodies (mAbs), MEM-E/02 or 3D12 bind to the peptide sequences in β2m-free HLA-E, whi
- PMID 24105714
- Phase I clinical trial of peptide vaccination with URLC10 and VEGFR1 epitope peptides in patients with advanced gastric cancer.
- Higashihara Y, Kato J, Nagahara A, Izumi K, Konishi M, Kodani T, Serizawa N, Osada T, Watanabe S.Author information Department of Gastroenterology, Juntendo University School of Medicine, Tokyo, Japan.AbstractPeptide vaccine treatment has attracted attention in recent years as a new therapy option for chemotherapy‑resistant, advanced, unresectable cancer. The safety of peptide vaccination with HLA-A*2402-restricted URLC10-A24-177 and VEGFR1-A12-9 1084 epitope peptides (fixed 2-mg dose) was investigated in a phase I clinical trial of patients with advanced gastric cancer who were refractory to chemotherapy. We determined the HLA genotype of the subjects after enrollment, results of which were held by the evaluation committee and kept from both patients and investigators until completion of the study. The primary end‑point was safety of the peptide vaccination. The secondary end‑points were immunological responses and clinical outcome, which were compared between the HLA-A*2402-positive and HLA-A*2402-negative groups. The peptides were subcutaneously administered on day 1, 8, 15 and 22 within a 28-day treatment cycle. A total of 14 patients was enrolled in this study; 12 of the 14 patients received 4 or more vaccinations (at least 1 course). No patient had a severe treatment-related adverse event. Findings from evaluation of clinical responses after a single course showed that 4 cases had stable disease and 8 cases had progressive disease. The median overall survival time (MST) for the 12 patients was 3.9 months. The MSTs in the HLA-A*2402‑positive and HLA-A*2402‑negative groups were, 4.2 and 3.6 months (p=0.9164), respectively. The results of this study showed that vaccination with URLC10 and VEGFR1 peptides was a safe treatment for advanced gastric cancer. This trial was registered with University Hospital Medical Information Network (UMIN, no. 000002409).
- International journal of oncology.Int J Oncol.2014 Mar;44(3):662-8. doi: 10.3892/ijo.2013.2242. Epub 2013 Dec 31.
- Peptide vaccine treatment has attracted attention in recent years as a new therapy option for chemotherapy‑resistant, advanced, unresectable cancer. The safety of peptide vaccination with HLA-A*2402-restricted URLC10-A24-177 and VEGFR1-A12-9 1084 epitope peptides (fixed 2-mg dose) was investigated
- PMID 24398900
- Upregulated microRNA-301a in breast cancer promotes tumor metastasis by targeting PTEN and activating Wnt/β-catenin signaling.
- Ma F1, Zhang J1, Zhong L1, Wang L1, Liu Y1, Wang Y1, Peng L2, Guo B3.Author information 1Department of General Surgery, the Second Affiliated Hospital of Harbin Medical University, Harbin, China.2Department of General Surgery, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.3Department of General Surgery, the Second Affiliated Hospital of Harbin Medical University, Harbin, China. Electronic address: baoliangguo2013@163.com.AbstractMicroRNAs (miRNAs) are strongly implicated in many cancers, including breast cancer. Recently, microRNA-301a (miR-301a) has been proved to play a substantial role in gastric cancer, but its functions in the context of breast cancer remain unknown. Here we report that miR-301a was markedly upregulated in primary tumor samples from patients with distant metastases and pro-metastatic breast cancer cell lines. Gain-of-function and loss-of-function studies showed that ectopic overexpression of miR-301a promoted breast cancer cell migration, invasion and metastasis both in vitro and in vivo. Notably, Wnt/β-catenin signaling was hyperactivated in metastatic breast cancer cells that express miR-301a, and mediated miR-301a-induced invasion and metastasis. Furthermore, miR-301a directly targeted and suppressed PTEN, one negative regulator of the Wnt/β-catenin signaling cascade. These results demonstrate that miR-301a maintains constitutively activated Wnt/β-catenin signaling by directly targeting PTEN, which promotes breast cancer invasion and metastasis. Taken together, our findings reveal a new regulatory mechanism of miR-301a and suggest that miR-301a might be a potential target in breast cancer therapy.
- Gene.Gene.2014 Feb 10;535(2):191-7. doi: 10.1016/j.gene.2013.11.035. Epub 2013 Dec 4.
- MicroRNAs (miRNAs) are strongly implicated in many cancers, including breast cancer. Recently, microRNA-301a (miR-301a) has been proved to play a substantial role in gastric cancer, but its functions in the context of breast cancer remain unknown. Here we report that miR-301a was markedly upregulate
- PMID 24315818
Japanese Journal
- 横行結腸癌が胃結腸瘻を形成した同時性多発大腸癌の1例
- 高橋 道長,後藤 慎二,上野 達也,佐藤 俊,前田 晋平,内藤 広郎
- 日本臨床外科学会雑誌 75(1), 121-127, 2014
- 症例は64歳の男性．全身倦怠感と眩暈を主訴に近医を受診．低蛋白血症と胃体部大弯の隆起性病変を指摘され，当院紹介となった．初診時，著明な体幹の羸痩と四肢の浮腫がみられ，未消化下痢と口からの便臭を認めた．精査にて，胃結腸瘻を伴う横行結腸癌と同時性のRb領域の進行直腸癌と診断された．経腸栄養等で栄養状態の改善を図ったが効果なく，先ず左結腸切除+胃大弯側部分切除+脾摘出術によって腫瘤を切除し，横行結腸人工 …
- NAID 130004679173
- 原発性多発小腸癌の1例
- 吉岡 将史,進士 誠一,菅 隼人,山田 岳史,小泉 岐博,高田 英志,河越 哲郎,三井 啓吾,松田 陽子,内田 英二
- Nippon Shokakibyo Gakkai Zasshi 111(8), 1594-1601, 2014
- NSAIDsを長期服用し胃潰瘍の既往を持つ62歳女性．腸閉塞で入院．回腸に2カ所の狭窄部を認め，小腸部分切除術を行ったところ低分化腺癌であった．転移性小腸癌を疑い全身検索したが，他に病変を認めなかった．原発性多発小腸癌の最終診断で追加腸切除を行い，所属リンパ節に転移を認めた．多発する小腸狭窄例において原発性小腸癌も鑑別診断として考慮する必要がある．
- NAID 130004678082
- 孤立性肋骨転移で発見され集学的治療が奏効した進行胃癌の1例
- 宮本 昌武,三澤 俊一,桐井 靖,高木 洋行,太田 浩良
- 日本消化器外科学会雑誌 47(7), 381-387, 2014
- 症例は73歳の男性で，右胸背部痛を主訴に受診しCTにて右第6肋骨に転移性骨腫瘍を指摘された．精査にて胃噴門部の1型胃癌，孤立性肋骨転移と診断した．導入治療としてS-1単剤による化学療法を施行し肋骨転移はcomplete responseとなったため，胃全摘，D2郭清を施行した．病理組織学的検査所見では中分化型腺癌，T1b (SM)，int，INFb，ly (1)，v (1)，pN0，H0，P0， …
- NAID 130004561030
Related Links
- Gastric cancer (GC) is currently the second leading cause of cancer death worldwide; unfortunately, most patients will present with locally advanced or metastatic disease. Despite recent progress in diagnosis, surgery ...
- Patients with metastatic gastric cancer have a poor outcome. The development of new combinations of chemotherapy has led to steady but only modest gains in overall survival with largest effects reported with two- and ...
Related Pictures
★リンクテーブル★
| リンク元 | 「転移性胃癌」 |
| 関連記事 | 「gastric」「metastatic」「cancer」「gastric cancer」 |
「転移性胃癌」
「gastric」
- adj.
- 胃の
「metastatic」
- 転移性の
「cancer」